Last reviewed · How we verify
oNKord®
At a glance
| Generic name | oNKord® |
|---|---|
| Sponsor | Glycostem Therapeutics BV |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Registry of Patients Having Received oNKord®
- A Trial to Evaluate the Safety and Efficacy of oNKord® in Subjects With Acute Myeloid Leukemia (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- oNKord® CI brief — competitive landscape report
- oNKord® updates RSS · CI watch RSS
- Glycostem Therapeutics BV portfolio CI